NASDAQ:LNTH

Lantheus (LNTH) Stock Forecast, Price & News

$69.64

+0.11 (+0.16%)

(As of 03:28 PM ET)

Compare

Today's Range: $68.44
▼
$70.44
50-Day Range: $60.27
▼
$87.95
52-Week Range: $47.46
▼
$100.85

Volume: 722,924 shs
Average Volume: 1.02 million shs
Market Capitalization: $4.77 billion

P/E Ratio: 169.85
Dividend Yield: N/A
Price Target: $119.33

Lantheus MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 71.9% Upside
$119.33 Price Target
Short Interest: Bearish
7.48% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.67
Upright™ Environmental Score
News Sentiment: 0.71
Based on 8 Articles This Week
Insider Trading: Selling Shares
$1.54 M Sold Last Quarter
Proj. Earnings Growth: 7.71%
From $5.19 to $5.59 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

136th out of 972 stocks

Diagnostic Substances Industry

3rd out of 13 stocks

3.5

Analyst's Opinion

Consensus Rating
Lantheus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $119.33, Lantheus has a forecasted upside of 71.9% from its current price of $69.44.
Amount of Analyst Coverage
Lantheus has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.48% of the float of Lantheus has been sold short.
Short Interest Ratio / Days to Cover
Lantheus has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Lantheus has recently decreased by 3.65%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Lantheus does not currently pay a dividend.
Dividend Growth
Lantheus does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Lantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.
Environmental Sustainability
The Environmental Impact score for Lantheus is -1.67.

2.6

News and Social Media Coverage

News Sentiment
Lantheus has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Lantheus this week, compared to 5 articles on an average week.
Search Interest
21 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,542,833.00 in company stock.
Percentage Held by Insiders
Only 1.50% of the stock of Lantheus is held by insiders.
Percentage Held by Institutions
99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Lantheus are expected to grow by 7.71% in the coming year, from $5.19 to $5.59 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lantheus is 169.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.00.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lantheus is 169.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 120.68.
Price to Book Value per Share Ratio
Lantheus has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lantheus (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.

LNTH Price History

30 days | 90 days | 365 days | Advanced Chart

LNTH Stock News Headlines

September 28, 2023 | benzinga.com

Looking At Lantheus Holdings's Recent Unusual Options Activity

September 27, 2023 | americanbankingnews.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of "Buy" from Brokerages

September 29, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 21, 2023 | finance.yahoo.com

Wall Street Bulls Look Optimistic About Lantheus Holdings (LNTH): Should You Buy?

September 5, 2023 | finance.yahoo.com

Wall Street Analysts Think Lantheus Holdings (LNTH) Is a Good Investment: Is It?

September 1, 2023 | finance.yahoo.com

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

August 30, 2023 | seekingalpha.com

Lantheus: Growth Well Priced In, Profitability Next Hurdle (Rating Downgrade)

August 30, 2023 | seekingalpha.com

Lantheus: Not Quite Ready To Take The Plunge

September 29, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 19, 2023 | money.usnews.com

Lantheus Holdings Inc

August 18, 2023 | seekingalpha.com

Lantheus to discontinue radiotherapy Azedra

August 8, 2023 | markets.businessinsider.com

Mizuho Securities Remains a Buy on Lantheus (LNTH)

August 7, 2023 | markets.businessinsider.com

Lantheus (LNTH) Receives a Buy from Truist Financial

August 4, 2023 | finance.yahoo.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2023 Earnings Call Transcript

August 4, 2023 | finance.yahoo.com

Should You Be Concerned About Lantheus Holdings, Inc.'s (NASDAQ:LNTH) ROE?

August 4, 2023 | markets.businessinsider.com

B.Riley Financial Keeps Their Buy Rating on Lantheus (LNTH)

August 3, 2023 | benzinga.com

Lantheus Holdings Unusual Options Activity For August 03

August 3, 2023 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Lantheus (LNTH)

August 3, 2023 | seekingalpha.com

Lantheus Holdings, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 3, 2023 | washingtonpost.com

Lantheus Holdings: Q2 Earnings Snapshot

August 3, 2023 | finance.yahoo.com

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

August 3, 2023 | finance.yahoo.com

Lantheus Holdings (LNTH) Surpasses Q2 Earnings and Revenue Estimates

July 28, 2023 | finance.yahoo.com

Lantheus (LNTH) to Report Q2 Earnings: What's in the Cards?

July 23, 2023 | markets.businessinsider.com

Truist Financial Remains a Buy on Lantheus (LNTH)

July 20, 2023 | finance.yahoo.com

Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time

July 17, 2023 | markets.businessinsider.com

Lantheus (LNTH) Gets a Buy from Truist Financial

July 12, 2023 | finance.yahoo.com

Is It Worth Investing in Lantheus Holdings (LNTH) Based on Wall Street's Bullish Views?

See More Headlines

Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Company Calendar

Last Earnings: 8/03/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LNTH
CUSIP: N/A
CIK: 1521036
Web: www.lantheus.com
Phone: (978) 671-8001
Fax: 978-671-8860
Employees: 698
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $119.33
High Stock Price Forecast: $130.00
Low Stock Price Forecast: $104.00
Forecasted Upside/Downside: +71.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.41
Trailing P/E Ratio: 169.59
Forward P/E Ratio: 13.40
P/E Growth: N/A
Net Income: $28.07 million
Net Margins: 2.97%
Pretax Margin: 1.72%
Return on Equity: 67.18%
Return on Assets: 27.42%

Debt

Debt-to-Equity Ratio: 1.01
Current Ratio: 4.88
Quick Ratio: 4.55

Sales & Book Value

Annual Sales: $935.06 million
Price / Sales: 5.09
Cash Flow: $5.04 per share
Price / Cash Flow: 13.79
Book Value: $6.50 per share
Price / Book: 10.70

Miscellaneous

Outstanding Shares: 68,430,000
Free Float: 67,405,000
Market Cap: $4.76 billion
Optionable: Optionable
Beta: 0.68

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Ms. Mary Anne Heino (Age 63)
CEO & Director
Comp: $2.23M

Mr. Paul M. Blanchfield (Age 42)
Pres
Comp: $962.41k

Mr. Robert J. Marshall Jr. (Age 56)
CFA, CFO & Treasurer
Comp: $1.06M

Mr. Daniel M. Niedzwiecki (Age 46)
Chief Admin. Officer, Gen. Counsel & Corp. Sec.
Comp: $871.93k

Mr. Etienne Montagut (Age 48)
Chief Bus. Officer
Comp: $789.15k

Ms. Andrea Sabens (Age 44)
Chief Accounting Officer

Ms. Dorothy Barr
Sr. VP of Manufacturing & Technical Operations

Mr. Mark Richard Kinarney
Sr. Director of Investor Relations

Ms. Linda S. Lennox (Age 57)
VP of Corp. Communications & Chief of Staff

Ms. Carol Walker (Age 60)
Sr. VP of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LNTH Stock - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings or view top-rated stocks.
What is Lantheus' stock price forecast for 2023?: 5 equities research analysts have issued 1 year price targets for Lantheus' stock. Their LNTH share price forecasts range from $104.00 to $130.00. On average, they anticipate the company's stock price to reach $119.33 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price.
View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts.
How have LNTH shares performed in 2023?: Lantheus' stock was trading at $50.96 at the start of the year. Since then, LNTH stock has increased by 36.4% and is now trading at $69.53.
View the best growth stocks for 2023 here.
When is Lantheus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our LNTH earnings forecast.
How were Lantheus' earnings last quarter?: Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, August, 3rd. The medical equipment provider reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.17. The medical equipment provider had revenue of $321.70 million for the quarter, compared to analyst estimates of $306.48 million. Lantheus had a trailing twelve-month return on equity of 67.18% and a net margin of 2.97%.
What ETFs hold Lantheus' stock?: ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), Invesco S&P MidCap Momentum ETF (XMMO), SPDR S&P Health Care Equipment ETF (XHE), Harbor Small Cap Explorer ETF (QWST), American Century Mid Cap Growth Impact (MID), Invesco S&P MidCap 400 Pure Growth ETF (RFG), First Trust Active Factor Small Cap ETF (AFSM) and SoFi Next 500 ETF (SFYX).
What guidance has Lantheus issued on next quarter's earnings?: Lantheus updated its third quarter 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $1.30-$1.35 for the period, compared to the consensus earnings per share estimate of $1.37. The company issued revenue guidance of $310.00 million-$315.00 million, compared to the consensus revenue estimate of $316.89 million.
What is Mary Anne Heino's approval rating as Lantheus' CEO?: 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).
When did Lantheus IPO?: (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.
What is Lantheus' stock symbol?: Lantheus trades on the NASDAQ under the ticker symbol "LNTH."
How do I buy shares of Lantheus?: Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lantheus' stock price today?: One share of LNTH stock can currently be purchased for approximately $69.53.
How much money does Lantheus make?: Lantheus (NASDAQ:LNTH) has a market capitalization of $4.76 billion and generates $935.06 million in revenue each year. The medical equipment provider earns $28.07 million in net income (profit) each year or $0.41 on an earnings per share basis.
How many employees does Lantheus have?: The company employs 698 workers across the globe.
How can I contact Lantheus?: Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.

This page (NASDAQ:LNTH) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial